Lincoln Pharmaceuticals Limited (LINCOLN.NS)
INR 552.6
(3.05%)
INR 552.6
(3.05%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.34 Billion INR | -10.54% |
| 2022 | 1.11 Billion INR | 9.39% |
| 2021 | 1.05 Billion INR | 13.99% |
| 2020 | 928.42 Million INR | 16.57% |
| 2019 | 765.76 Million INR | 7.03% |
| 2018 | 728.92 Million INR | 25.86% |
| 2017 | 577.69 Million INR | 15.97% |
| 2016 | 495.1 Million INR | 8.48% |
| 2015 | 478.93 Million INR | 42.7% |
| 2014 | 327.91 Million INR | 47.53% |
| 2013 | 217.02 Million INR | 38.05% |
| 2012 | 173.81 Million INR | 27.44% |
| 2011 | 138.67 Million INR | -6.43% |
| 2010 | 130.82 Million INR | 9.49% |
| 2009 | 119.48 Million INR | 20.38% |
| 2008 | 93.29 Million INR | 5.66% |
| 2007 | 93.93 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 227.32 Million INR | -10.51% |
| 2023 Q4 | 183.83 Million INR | -38.02% |
| 2023 FY | - INR | -10.54% |
| 2023 Q1 | 284.08 Million INR | 38.32% |
| 2023 Q2 | 398.42 Million INR | 40.25% |
| 2023 Q3 | 296.61 Million INR | -25.55% |
| 2022 Q2 | 346.22 Million INR | 47.92% |
| 2022 Q3 | 331.08 Million INR | -4.37% |
| 2022 Q4 | 205.38 Million INR | -37.97% |
| 2022 Q1 | 234.06 Million INR | 24.46% |
| 2022 FY | - INR | 9.39% |
| 2021 Q4 | 188.05 Million INR | -27.91% |
| 2021 FY | - INR | 13.99% |
| 2021 Q1 | 273.24 Million INR | 56.86% |
| 2021 Q2 | 327.31 Million INR | 19.79% |
| 2021 Q3 | 260.85 Million INR | -20.31% |
| 2020 Q3 | 207.31 Million INR | -30.35% |
| 2020 Q2 | 297.64 Million INR | 24.19% |
| 2020 Q1 | 239.66 Million INR | 95.11% |
| 2020 Q4 | 174.19 Million INR | -15.97% |
| 2020 FY | - INR | 16.57% |
| 2019 Q3 | 162.25 Million INR | -40.36% |
| 2019 Q4 | 122.83 Million INR | -24.3% |
| 2019 FY | - INR | 7.03% |
| 2019 Q1 | 203.42 Million INR | 114.67% |
| 2019 Q2 | 272.04 Million INR | 33.74% |
| 2018 Q1 | 255.9 Million INR | 143.57% |
| 2018 Q4 | 94.76 Million INR | -32.26% |
| 2018 Q2 | 235.18 Million INR | -8.09% |
| 2018 Q3 | 139.89 Million INR | -40.52% |
| 2018 FY | - INR | 25.86% |
| 2017 Q3 | 189.83 Million INR | 3.04% |
| 2017 FY | - INR | 15.97% |
| 2017 Q4 | 105.06 Million INR | -44.66% |
| 2017 Q2 | 184.22 Million INR | 86.89% |
| 2017 Q1 | 98.57 Million INR | 97.7% |
| 2016 FY | - INR | 8.48% |
| 2016 Q3 | 117.93 Million INR | -18.91% |
| 2016 Q2 | 145.42 Million INR | -19.44% |
| 2016 Q1 | 180.52 Million INR | 56.64% |
| 2016 Q4 | 49.86 Million INR | -57.72% |
| 2015 Q3 | 131.68 Million INR | 12.28% |
| 2015 Q1 | 114.44 Million INR | 82.53% |
| 2015 FY | - INR | 42.7% |
| 2015 Q2 | 117.28 Million INR | 2.49% |
| 2015 Q4 | 115.25 Million INR | -12.48% |
| 2014 Q2 | 119.83 Million INR | 67.08% |
| 2014 Q4 | 62.69 Million INR | -1.2% |
| 2014 Q3 | 63.45 Million INR | -47.04% |
| 2014 Q1 | 71.72 Million INR | 69.58% |
| 2014 FY | - INR | 47.53% |
| 2013 Q3 | 69.42 Million INR | 30.97% |
| 2013 Q1 | 50.39 Million INR | 51.26% |
| 2013 Q2 | 53 Million INR | 5.19% |
| 2013 Q4 | 42.29 Million INR | -39.08% |
| 2013 FY | - INR | 38.05% |
| 2012 Q4 | 33.31 Million INR | 5.59% |
| 2012 Q3 | 31.55 Million INR | -50.31% |
| 2012 Q2 | 63.5 Million INR | 129.91% |
| 2012 Q1 | 27.62 Million INR | 826.06% |
| 2012 FY | - INR | 27.44% |
| 2011 Q3 | 29.28 Million INR | 0.0% |
| 2011 FY | - INR | -6.43% |
| 2011 Q4 | -3.8 Million INR | -112.99% |
| 2010 FY | - INR | 9.49% |
| 2009 FY | - INR | 20.38% |
| 2008 FY | - INR | 5.66% |
| 2008 Q4 | 6.72 Million INR | 0.0% |
| 2007 FY | - INR | 0.0% |
| 2007 Q4 | 6.52 Million INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 86.031% |
| Hester Biosciences Limited | 539.47 Million INR | -149.008% |
| Aarti Drugs Limited | 3.24 Billion INR | 58.65% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 65.639% |
| Albert David Limited | 1.04 Billion INR | -28.496% |
| Alembic Limited | 1.11 Billion INR | -20.333% |
| Alkem Laboratories Limited | 24.19 Billion INR | 94.448% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -1072.357% |
| Bajaj HealthCare Limited | 406.23 Million INR | -230.674% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -10236.427% |
| Brooks Laboratories Limited | 41.72 Million INR | -3119.234% |
| Eris Lifesciences Limited | 6.98 Billion INR | 80.772% |
| FDC Limited | 3.38 Billion INR | 60.32% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 80.426% |
| Gufic Biosciences Limited | 1.48 Billion INR | 9.265% |
| Hikal Limited | 2.69 Billion INR | 50.104% |
| Ind-Swift Limited | 1.06 Billion INR | -26.126% |
| Innova Captab Limited | 1.66 Billion INR | 19.48% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 48.465% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -315.298% |
| Jubilant Pharmova Limited | 8 Billion INR | 83.221% |
| Lupin Limited | 36.96 Billion INR | 96.366% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -667.85% |
| Medico Remedies Limited | 129.09 Million INR | -940.577% |
| Morepen Laboratories Limited | 1.72 Billion INR | 22.169% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 12.521% |
| Orchid Pharma Limited | 1.41 Billion INR | 5.345% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 56.306% |
| RPG Life Sciences Limited | 1.28 Billion INR | -4.824% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -367.364% |
| Sigachi Industries Limited | 883.39 Million INR | -52.063% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 147.603% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 71.279% |
| Themis Medicare Limited | 562.6 Million INR | -138.767% |
| Unichem Laboratories Limited | 742.35 Million INR | -80.954% |
| Vaishali Pharma Limited | 31.71 Million INR | -4136.139% |
| Wanbury Limited | 985.49 Million INR | -36.31% |
| Windlas Biotech Limited | 781.72 Million INR | -71.842% |
| ZIM Laboratories Limited | 462.09 Million INR | -190.701% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 80.423% |
| Ipca Laboratories Limited | 13.29 Billion INR | 89.899% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.029% |
| Venus Remedies Limited | 711.8 Million INR | -88.722% |
| Sakar Healthcare Limited | 393.26 Million INR | -241.579% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 97.826% |
| Divi's Laboratories Limited | 25.43 Billion INR | 94.718% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 43.002% |
| Mankind Pharma Limited | 28.09 Billion INR | 95.219% |
| Sequent Scientific Limited | 549.8 Million INR | -144.329% |
| Laurus Labs Limited | 8 Billion INR | 83.221% |
| Neuland Laboratories Limited | 4.74 Billion INR | 71.709% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 85.61% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 88.158% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 97.611% |
| Amrutanjan Health Care Limited | 681.59 Million INR | -97.085% |
| Wockhardt Limited | 1.08 Billion INR | -24.382% |
| Bal Pharma Limited | 345.59 Million INR | -288.702% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.478% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 9.175% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -488.727% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 78.277% |
| Shilpa Medicare Limited | 2.58 Billion INR | 48.094% |
| Valiant Laboratories Limited | 12.73 Million INR | -10444.956% |
| Ajanta Pharma Limited | 12.56 Billion INR | 89.309% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -2874.254% |
| Granules India Limited | 8.6 Billion INR | 84.387% |
| Medicamen Biotech Limited | 245.66 Million INR | -446.822% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -212.2% |
| Piramal Enterprises Limited | -3.86 Billion INR | 134.791% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 96.163% |
| NATCO Pharma Limited | 18.79 Billion INR | 92.853% |
| Suven Life Sciences Limited | -992.78 Million INR | 235.309% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1723.801% |
| Strides Pharma Science Limited | 3.76 Billion INR | 64.318% |
| Indoco Remedies Limited | 2.64 Billion INR | 49.252% |
| Alpa Laboratories Limited | 229.96 Million INR | -484.152% |
| Lasa Supergenerics Limited | -65.08 Million INR | 2164.109% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 136.0% |